XML 48 R34.htm IDEA: XBRL DOCUMENT
v3.19.2

Related Parties Transactions (Tables) | 3 Months Ended | 12 Months Ended
--- | --- | ---
Mar. 31, 2019 | Dec. 31, 2018
Related Party Transactions [Abstract] |  |
Schedule of related party transactions |
Name of entity or Individual |  | Relationship with the Company and its subsidiaries
BioFirst Corporation (the "BioFirst") |  | Entity controlled by controlling beneficiary shareholder of Yuangene
BioFirst (Australia) Pty Ltd. (the "BioFirst (Australia)") |  | 100% owned by BioFirst; Entity controlled by controlling beneficiary shareholder of YuanGene
Lion Arts Promotion Inc. (the "LION") |  | Controlling shareholder of BioLite Inc.
LionGene Corporation (the "LionGene") |  | Shareholder of the Company; entity controlled by controlling beneficiary shareholder of YuanGene
Rgene Corporation (the "Rgene") |  | Shareholder of the Company; entity controlled by controlling beneficiary shareholder of Yuangene
Yuangene Corporation (the "Yuangene") |  | Controlling beneficiary shareholder of the Company
AsianGene Corporation (the "AsianGene") |  | Shareholder; entity controlled by controlling beneficiary shareholder of Yuangene
Keypoint Technology Ltd. (the "Keypoint') |  | The Chairman of Keypoint is Eugene Jiang's mother.
Yoshinobu Odaira (the "Odaira") |  | Director of the Company
GenePharm Inc. (the "GenePharm") |  | Mr. George Lee, the Director and Chairman of Biokey, is the Chairman of Genepharm.
Mr. Tsung-Shann Jiang, Ms. Shu-Ling Jiang and Mr. Eugene Jiang (the "Jiangs") |  | Mr. Tsung-Shann Jiang, the controlling beneficiary shareholder of the Company and Rgene, the chairman and CEO of the BioLite Inc. and the President and a member of board of directors of BioFirst, Ms. Shu-Ling Jiang, Mr. Tsung-Shann Jiang's wife, is a member of board of directors of the Company and the chairman of LION and BioFirst. Mr. Eugene Jiang is Mr. and Ms. Jiang's son. Mr. Eugene Jiang is the chairman, and majority shareholder of the Company and a member of board of directors of BioLite Inc.
Name of entity or Individual |  | Relationship with the Company and its subsidiaries
BioLite Inc. (the "BioLite") |  | Shareholder of the Company; entity controlled by controlling beneficiary shareholder of YuanGene
BioFirst Corporation (the "BioFirst") |  | Entity controlled by controlling beneficiary shareholder of YuanGene
BioFirst (Australia) Pty Ltd. (the BioFirst (Australia)") |  | 100% owned by BioFirst; Entity controlled by controlling beneficiary shareholder of YuanGene
Rgene Corporation (the "Rgene") |  | Shareholder of the Company; entity controlled by controlling beneficiary shareholder of YuanGene
LionGene Corporation (the "LionGene") |  | Shareholder of the Company; entity controlled by controlling beneficiary shareholder of YuanGene
YuanGene Corporation (the "YuanGene") |  | Controlling beneficiary shareholder of the Company
AsianGene Corporation (the "AsianGene") |  | Shareholder; entity controlled by controlling beneficiary shareholder of YuanGene
Eugene Jiang |  | Former President and Chairman
Keypoint Technology Ltd. (the "Keypoint') |  | The Chairman of Keypoint is Eugene Jiang's mother.
Yoshinobu Odaira (the "Odaira") |  | Director of the Company
Euro-Asia Investment & Finance Corp Ltd. (the "Euro-Asia") |  | Shareholder of the Company
Kimho Consultants Co., Ltd. (the "Kimho") |  | Shareholder of the Company
BioKey, Inc. (the "BioKey") |  | One of wholly-owned subsidiaries of ABVC upon closing of the Mergers on February 8, 2019
Schedule of accounts receivable related parties |
|  | March 31, |  |  | December 31, |
|  | 2019 |  |  | 2018 |
GenePharm Inc. |  | $ | 142,265 |  |  | $ | - |
Total |  | $ | 142,265 |  |  | $ | - |
Schedule of other receivable related parties |  |
|  | December 31, |  |  | December 31, |
|  | 2018 |  |  | 2017 |
BioFirst (Australia) |  | $ | 40,000 |  |  | $ | - |
Total |  | $ | 40,000 |  |  | $ | - |
Schedule of due from related parties |
|  | March 31, |  |  | December 31, |
|  | 2019 |  |  | 2018 |
Rgene Corporation |  | $ | 17,550 |  |  | $ | 19,477 |
BioFirst (Australia) |  | $ | 40,675 |  |  | $ | 40,000 |
Total |  | $ | 58,225 |  |  | $ | 59,477 |
Schedule of amount due to related party |
|  | March 31, |  |  | December 31, |
|  | 2019 |  |  | 2018 |
Lion Arts Promotion Inc. |  | $ | 64,964 |  |  | $ | 65,495 |
LionGene Corporation |  |  | 430,940 |  |  |  | 458,348 |
BioFirst Corporation |  |  | 6,248,105 |  |  |  | 6,428,643 |
AsianGene Corporation |  |  | 160,000 |  |  |  | 160,000 |
YuanGene Corporation |  |  | 92,690 |  |  |  | 92,690 |
The Jiangs |  |  | 598,085 |  |  |  | 539,920 |
Total |  | $ | 7,594,784 |  |  | $ | 7,745,096 |
|  | December 31, |  |  | December 31, |
|  | 2018 |  |  | 2017 |
BioLite Inc. |  | $ | 58,684 |  |  | $ | 109,220 |
BioFirst Corporation |  |  | 4,151,301 |  |  |  | 3,957,000 |
AsianGene Corporation |  |  | 160,000 |  |  |  | 160,000 |
YuanGene Corporation |  |  | 92,690 |  |  |  | 3,000 |
Eugene Jiang |  |  | 100 |  |  |  | 100 |
Total |  | $ | 4,462,775 |  |  | $ | 4,229,320 |

X
- Definition Tabular of other receivable related parties. + References No definition available. + Details
Name: | abvcd_OtherReceivableRelatedPartiesTableTextBlock
Namespace Prefix: | abvcd_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of due from related parties. + References No definition available. + Details
Name: | abvcd_ScheduleOfDueFromRelatedPartiesTableTextBlock
Namespace Prefix: | abvcd_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of related party transactions. Amount due to related party. + References No definition available. + Details
Name: | abvcd_ScheduleOfRelatedPartyTransactionsAmountDueToRelatedParty
Namespace Prefix: | abvcd_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_RelatedPartyTransactionsAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of the various types of trade accounts and notes receivable and for each the gross carrying value, allowance, and net carrying value as of the balance sheet date. Presentation is categorized by current, noncurrent and unclassified receivables. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.3,4) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 + Details
Name: | us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of related party transactions. Examples of related party transactions include, but are not limited to, transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners and (d) affiliates. + References No definition available. + Details
Name: | us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration